|
|
|
|
Quince Therapeutics Inc (NASDAQ: QNCX) |
|
Price: $1.3000
$-0.06 
-4.412%
|
| Day's High:
| $1.43
| Week Perf:
| 8.33 %
|
| Day's Low: |
$ 1.30 |
30 Day Perf: |
52.94 % |
| Volume (M): |
376 |
52 Wk High: |
$ 2.45 |
| Volume (M$): |
$ 489 |
52 Wk Avg: |
$1.28 |
| Open: |
$1.41 |
52 Wk Low: |
$0.56 |
|
|
| Market Capitalization (Millions $) |
57 |
| Shares
Outstanding (Millions) |
44 |
| Employees |
36 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-15 |
| Cash Flow (TTM) (Millions $) |
-14 |
| Capital Exp. (TTM) (Millions $) |
0 |
Quince Therapeutics Inc
Company Address: 611 Gateway Boulevard, South San Francisco 94080 CA
Company Phone Number: 910-5717 Stock Exchange / Ticker: NASDAQ QNCX
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Business Update
Published Tue, Mar 25 2025 4:12 AM UTC
Unlocking Potential: Quince Therapeutics Fiscal Year 2024 Financial Results and Strategic Developments in Rare Disease Therapeutics Quince Therapeutics, Inc. (Nasdaq: QNCX), a pioneering biotechnology enterprise headquartered in South San Francisco, is steadfastly advancing the therapeutic landscape for rare diseases by leveraging the intrinsic potential of patient biology....
|
| Business Update
Published Tue, Nov 12 2024 3:36 AM UTC
In a significant advancement for the field of pediatric neurology and rare disease therapeutics, Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology firm based in South San Francisco, has presented safety data from its Phase 3 ATTeST (Ataxia-Telangiectasia Trial with the EryDex SysTem; NCT02770807) clinical trial at the 53rd Child Neurology Society (CNS) Ann...
|
| Business Update
Published Thu, Aug 15 2024 12:09 PM UTC
Quince Therapeutics Unveils Promising Data on EryDex Treatment for Ataxia-Telangiectasia and Reports Encouraging Financial Outlook In the realm of biotechnology, the quest for effective treatments for rare diseases remains one of the most formidable challenges. Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage company at the forefront of this endeavor, has recently ma...
|
| Business Update
Published Mon, Jun 3 2024 11:38 AM UTC
South San Francisco, Calif. Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for its innovative EryDex System. This decision aims to expedite the development and review of the EryDex System, specifically targeting patients suffering from Ataxia-Telangiectasia...
|
| Business Update
Published Mon, May 13 2024 1:47 PM UTC
Quince Therapeutics, a distinguished player in the biotechnology industry, is persistently pushing the boundaries of innovation with its unique patient-driven drug delivery technology. Its unwavering dedication to revolutionizing the delivery of rare disease therapeutics is the company s unique selling point that sets it apart from its competitors. With the close of the firs...
|
| Per Share |
Current |
| Earnings (TTM) |
-1.35 $ |
| Revenues (TTM) |
-
|
| Cash Flow (TTM) |
- |
| Cash |
0.18 $
|
| Book Value |
0.42 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-1.35 $
|
| Revenues (TTM) |
- |
| Cash Flow (TTM) |
- |
| Cash |
0.18 $
|
| Book Value |
0.42 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
